Information for "Ruxolitinib in COVID19 Hyperinflammation as well as Haematologic Malignancies"
Basic information
| Display title | Ruxolitinib in COVID19 Hyperinflammation as well as Haematologic Malignancies |
| Default sort key | Ruxolitinib in COVID19 Hyperinflammation as well as Haematologic Malignancies |
| Page length (in bytes) | 4,287 |
| Page ID | 824397 |
| Page content language | en - English |
| Page content model | wikitext |
| Indexing by robots | Allowed |
| Number of redirects to this page | 0 |
Page protection
| Edit | Allow all users (infinite) |
| Move | Allow all users (infinite) |
Edit history
| Page creator | 196.199.119.41 (talk) |
| Date of page creation | 10:58, 14 November 2022 |
| Latest editor | 196.199.119.41 (talk) |
| Date of latest edit | 10:58, 14 November 2022 |
| Total number of edits | 1 |
| Total number of distinct authors | 1 |
| Recent number of edits (within past 90 days) | 0 |
| Recent number of distinct authors | 0 |
